Loading
Life sciences · Journal article
Molecular Medicine · October 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Gemcitabine remains the primary chemotherapeutic agent for multiple solid tumours; however, the development of resistance greatly limits its effectiveness. This resistance is multifactorial, including mechanisms affecting intracellular drug concentration, enhancement of DNA repair mechanisms, evasion of apoptosis, and others. Increasing evidence suggests that cancer stem cells (CSCs) play a key role in driving gemcitabine chemoresistance. CSCs show intrinsic features such as quiescence, enhanced DNA repair, epithelial–mesenchymal transition (EMT) traits, and overexpression of drug efflux transporters, all of which help them survive gemcitabine treatment. Additionally, dysregulated signalling pathways like Hedgehog, Notch, Wnt/β-catenin, and PI3K/AKT/mTOR are closely linked to CSC maintenance and gemcitabine resistance. The tumour microenvironment further supports CSC survival through hypoxia, stromal interactions, and cytokine signalling, creating a protective niche that reduces drug effectiveness. Understanding how CSCs contribute to gemcitabine resistance opens up new treatment options, such as targeting CSC markers (CD44, CD24, EpCAM, ALDH1), modulating abnormal signalling pathways, and using combination strategies to eliminate both bulk tumour cells and CSCs. This review emphasizes the clinical importance of CSCs in mediating gemcitabine resistance and underscores the need for CSC-targeted therapies to improve patient outcomes.